Dual-treatment of JX06 and gefitinib significantly inhibited tumor growth in vivo. (IMAGE)
Caption
The PC-9/G cells (5 × 106 cells) were inoculated subcutaneously on the back of nude mice. When the tumor reached approximately 5 × 5 mm2, the nude mice were randomly divided into four groups (n = 5 per group) and treated with saline, gefitinib (25 mg/kg), JX06 (30 mg/kg), or gefitinib (25 mg/kg) plus JX06 (30 mg/kg). (A–C) Tumor volumes and weights were analyzed, and dual-treatment of JX06 and gefitinib significantly inhibited tumor volumes and tumor weights. (D) Animal weights between the four groups did not show any significant difference. (E) Representative images of immunohistochemical staining of Ki67 and CD31 in paraffin-embedded xenograft tumor tissues, and the expression levels of Ki67 and CD31 were quantified for six microscopic fields of the tumor samples. Data were statistically analyzed with Student’s t-test, and values were shown as mean ± standard deviation. ∗P < 0.05 and ∗∗P < 0.01.
Credit
Zhihao Zhou, Ruike Zhang, Zhaoyang Zhang, Liyuan Zhang, Wei Wang, Wenjing Liu, Chunyang Zhang, Gen Lin, Weimiao Yu, Bo Xu, Lin Wang, Bing-Hua Jiang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND